Madrigal Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
Madrigal Pharmaceuticals has raised $1.1B across 3 funding rounds on record, the most recent an undisclosed round of $600M announced in Mar 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Madrigal Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Madrigal Pharmaceuticals Funding Rounds
Madrigal Pharmaceuticals raised $250M in a Post-IPO Debt announced in May 2022.
7 months later, an undisclosed round of $259M was announced in Dec 2022.
1.3 years later, an undisclosed round of $600M was announced in Mar 2024.
Madrigal Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Madrigal Pharmaceuticals Funding Compared to Other Biotechnology Startups
Madrigal Pharmaceuticals' latest round of $600M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Madrigal Pharmaceuticals in Biotechnology and Conshohocken
Companies Similar to Madrigal Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Madrigal Pharmaceuticals Funding FAQs
What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
How much funding has Madrigal Pharmaceuticals raised?
Madrigal Pharmaceuticals has raised $1.1B across 3 rounds on record. The most recent is an undisclosed round of $600M announced in Mar 2024.
When did Madrigal Pharmaceuticals last raise funding?
Madrigal Pharmaceuticals' most recent funding round on record is an undisclosed round of $600M, announced in Mar 2024.
Who founded Madrigal Pharmaceuticals?
FundedIQ lists Rebecca Taub (Founder) at Madrigal Pharmaceuticals.
Where is Madrigal Pharmaceuticals headquartered?
Madrigal Pharmaceuticals is based in Conshohocken, Pennsylvania, United States.
How many employees does Madrigal Pharmaceuticals have?
Madrigal Pharmaceuticals is in the 51-100 employee band.
How does Madrigal Pharmaceuticals' funding compare to other Biotechnology startups?
Madrigal Pharmaceuticals' latest round of $600M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Madrigal Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Madrigal Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.